Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells-Reference-Cited by-同舟云学术

Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells

Published:2017-12-20 Issue:12 Volume:12 Page:e0189007
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Liu Chun-Yu,Lau Ka-Yi,Hsu Chia-Chi,Chen Ji-Lin,Lee Chia-Han,Huang Tzu-Ting,Chen Yi-Ting,Huang Chun-Teng,Lin Po-Han,Tseng Ling-Ming^ORCID

Funder

Taiwan Clinical Oncology Research Foundation

Ministry of Science and Technology (VN)

Yang-Ming Branch of Taipei City Hospital

Taipei Veterans General Hospital

TVGH-NTUH Joint Research Program

Ministry of Health and Welfare (TW)

Ministry of Health and Welfare

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. Targeting triple-negative breast cancer: optimising therapeutic outcomes;K Gelmon;Ann Oncol,2012

2. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer;K Kobayashi;Surg Today,2016

3. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up;L Malorni;Breast Cancer Res Treat,2012

4. New strategies for triple-negative breast cancer—deciphering the heterogeneity;IA Mayer;Clin Cancer Res,2014

5. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6;PL Toogood;J Med Chem,2005

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Analysis of CDK4/6 Inhibitors (Ribociclib and Palbociclib) combined with Enzalutamide in Triple-negative breast cancer cells;International Journal of Life Sciences and Biotechnology;2024-04-15

2. Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer;International Journal of Molecular Sciences;2024-02-02

3. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?;Clinical Breast Cancer;2023-12

4. Breast Cancer Treatment: To tARget or Not? That Is the Question;Cancers;2023-11-30

5. Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment;Molecules;2023-11-09